JWK007 Single intravenous infusion administration
2023-1285
Phase 1 mab active
Quick answer
JWK007 Single intravenous infusion administration for Duchenne Muscular Dystrophy is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Duchenne Muscular Dystrophy
- Phase
- Phase 1
- Modality
- mab
- Status
- active